复发性卵巢癌治疗中患者价值观、偏好与期望的系统综述
该系统综述检索2000年1月1日至2016年12月13日Medline、Embase、CINAHL和PsycINFO,纳入10项来自5个国家的关于铂敏感复发性或难治性卵巢癌女性价值观、偏好或期望的研究。结果发现患者常高估化疗治愈能力,既往耐受化疗者更接受副作用,患者比医护人员更愿接受化疗副作用,24%的患者持续选择治疗而非姑息治疗。结论强调沟通预后、不良反应和症状管理的重要性,复发性卵巢癌化疗应结合医学限制与患者偏好个案化管理。
要点
- 患者即使经过咨询仍高估化疗的治愈能力,一项研究中92%的患者对治愈有高期望。
- 既往化疗耐受良好的患者更可能接受化疗副作用,患者比医护人员更愿接受副作用。
- 24%的显著少数患者持续选择治疗而非姑息治疗,患者重视总生存和无进展生存。
核心结论
- 这些发现总体上强调与患者沟通预后、不良反应和症状管理以帮助协商决策过程的重要性。
- 复发性卵巢癌化疗应结合医学限制和患者偏好进行个案化管理。
研究设计与样本
- 系统综述检索Medline、Embase、CINAHL和PsycINFO,时间范围为2000年1月1日至2016年12月13日。
- 纳入10项来自5个国家的关于铂敏感复发性或难治性卵巢癌女性价值观、偏好或期望的研究。
主要发现
- 患者即使经过咨询仍高估化疗的治愈能力,一项研究中92%的患者在完成治疗期望清单后对治愈有高期望。
- 另一项研究观察到患者常被诊断时提供的信息淹没,患者报告听到的内容与临床医生所说的可能存在差异。
- 既往化疗耐受良好的患者更可能接受化疗副作用。
- 当治疗为治愈意图或总生存增加时,患者更愿意接受化疗及相关副作用。
- 患者重视总生存和无进展生存,24%的显著少数患者持续选择治疗而非姑息治疗。
关键数值与推荐
- 一项研究中92%的患者在完成治疗期望清单后对治愈有高期望。
- 24%的患者持续选择治疗而非姑息治疗。
- 共纳入10项研究,代表5个国家。
临床怎么用
- 作者认为这些发现强调与患者沟通预后、不良反应和症状管理以帮助协商决策过程的重要性。
- 作者认为复发性卵巢癌化疗应结合医学限制和患者偏好进行个案化管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: It is our belief that patient preference should play a significant role in disease management of recurrent ovarian cancer. Since cure is seldom an endpoint in this circumstance, patients' attitudes toward the risks and benefits of chemotherapy versus palliation are relevant. METHODS: Medline, Embase, CINAHL and PsycINFO from were searched from January 1, 2000 to December 13, 2016 for studies of values, preferences or expectations of women with platinum-sensitive recurrent or refractory ovarian cancer. RESULTS: Ten studies representing five countries met inclusion criteria. Although there was regional variation in preference for palliation over treatment, certain themes emerged. 1) Patients, even in the context of counselling overestimated the curative capability of chemotherapy. In one study 92% of patients had high expectations of healing after completing an expectation of treatment checklist. Another study observed that patients are often overwhelmed by information provided at diagnosis and there can be a discrepancy between what patients report to have heard and what the clinicians said. 2) Patients who had previously tolerated chemotherapy well were more likely to be accepting of the side-effects of chemotherapy. 3) Patients were more willing to accept chemotherapy and the related side effects when treatment was of curative intent or when overall survival was increased. 4) Patients valued both overall and progression free survival. 5) A significant minority (24%) consistently chose treatment over palliation. 6) Patients were more willing to accept the side effects of chemotherapy than were their health care providers. CONCLUSIONS: These findings, in aggregate, highlight the importance of communication with patients regarding prognosis, adverse effects and symptom management to help negotiate the decision making process. Chemotherapy in the recurrent setting should be managed on a case by case basis, combining both medical constraints and consideration to patient preferences.
引用
- A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2017. PMID: 28601379. doi:10.1016/j.ygyno.2017.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。